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IBDImpairment of epithelial barrier is observed in various intestinal disorders including inﬂammatory bowel
diseases (IBD). Numerous factorsmay cause temporary damage of the intestinal epithelium. A complex network
of highly divergent factors regulates healing of the epithelium to prevent inﬂammatory response. However, the
exact repair mechanisms involved in maintaining homeostatic intestinal barrier integrity remain to be clariﬁed.
In this study, we demonstrate that activation of M1 muscarinic acetylcholine receptor (mAChR) augments
the restitution of epithelial barrier function in T84 cell monolayers after ethanol-induced epithelial injury, via
ERK-dependent phosphorylation of focal adhesion kinase (FAK). We have shown that ethanol injury decreased
the transepithelial electrical resistance (TER) along with the reduction of ERK and FAK phosphorylation.
Carbachol (CCh) increased ERK and FAK phosphorylation with enhanced TER recovery, which was completely
blocked by either MT-7 (M1 antagonist) or atropine. The CCh-induced enhancement of TER recovery was also
blocked by either U0126 (ERK pathway inhibitor) or PF-228 (FAK inhibitor). Treatment of T84 cell monolayers
with interferon-γ (IFN-γ) impaired the barrier function with the reduction of FAK phosphorylation. The CCh-
induced ERK and FAK phosphorylation were also attenuated by the IFN-γ treatment. Immunological and binding
experiments exhibited a signiﬁcant reduction of M1 mAChR after IFN-γ treatment. The reduction of M1 mAChR
in inﬂammatory area was also observed in surgical specimens from IBD patients, using immunohistochemical
analysis. These ﬁndings provide important clues regarding mechanisms by which M1 mAChR participates in
the maintenance of intestinal barrier function under not only physiological but also pathological conditions.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Epithelial integrity of the gut is essential for preventing the invasion
of microorganisms and the development of inﬂammation in intestinal
submucosa. The intestinal epithelium is a highly selective barrier that
permits the absorption of nutrients from the gut lumen into thel Transduction, Department of
078-8510, Japan. Tel.: +81 166
niguchi).
ights reserved.circulation and at the same time restricts the passage of harmful and
potentially toxic compounds [1,2]. Disruption of intestinal barrier
integrity (leaky gut) may lead to the penetration of luminal bacterial
products into the submucosa to initiate local inﬂammation [1]. Mild
form of intestinal epithelial injury commonly occurs in many diseases,
which is rapidly repaired to reform the integrity of epithelial mono-
layers to prevent invasion of noxious compounds.
Findings on various tissues or cells reveal that focal adhesion kinase
(FAK) is one of the key regulators for the maintenance and repair of
barrier functions [3–7]. FAK is a non-receptor tyrosine kinase that
modulates various cell functions, including survival, proliferation, and
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group of important intracellular mediators of signal transduction to
various stimuli. The classical MAP kinase, ERK1/2 (ERK) has been asso-
ciated with the regulation of cellular proliferation and differentiation
[10,11]. The role of MAP kinase pathway in the regulation of the
paracellular permeability across epithelial cells has not been explored
extensively. However, several studies have reported the positive regula-
tion of epithelial barrier function as a result of the phosphorylation of
ERK [12,13].
Carbachol (CCh), an agonist of muscarinic acetylcholine receptors
(mAChRs), increased the phosphorylation of ERK and FAK in T84
cells [14]. Recent evidence implies the participation of mAChRs in the
tightness of epithelial integrity in the proximal colon [15]. These ﬁnd-
ings suggest the crucial role of mAChRs in the intestinal epithelium to
maintain and/or to repair barrier functions. However, the mechanisms
and signaling molecules downstream from mAChRs in the regulation
of barrier functions are still unknown.
The family of mAChRs belongs to a G-protein–coupled-receptor su-
perfamily. Five subtypes of mAChRs (M1–M5), with difference in signal
transduction, have been cloned [16,17]. Numerous studies revealed that
intestinal infection and inﬂammation impaired themuscarinic choliner-
gic response to the gut epithelium [18]. The exact signaling mechanism
of cholinergic hyporesponsiveness to the gut epithelium under inﬂam-
matory condition remains to be clariﬁed. We reported previously that
ERK and FAK are localized in the intestinal epithelial cells [19,20] and
may be involved in the modulation of barrier functions under normal
as well as inﬂammatory conditions. Impaired epithelial barrier function
is a common feature of the inﬂammatory bowel diseases (IBD) and is
caused, at least in part, by the elevated level of various cytokines.
Treatment of T84 epithelial cell monolayers with interferon-γ (IFN-γ),
one of those cytokines, has been shown to compromise their barrier
integrity with a decrease in transepithelial electrical resistance
(TER) and an increase in epithelial permeability [21,22]. Recently,
it has been demonstrated that AMP-activated protein kinase and
phosphatidylinositol 3′-kinase may be involved in IFN-γ-induced epi-
thelial barrier dysfunction [23–25]. However, the precise mechanism
of barrier dysfunction under the inﬂammatory condition is yet to be
elucidated.
In this study, we aimed to uncover the role of mAChRs and the
downstream signaling pathway in the maintenance and restitution of
the barrier function in human intestinal epithelial cells. We also sought
to investigate the cause of barrier dysfunction under inﬂammatory con-
dition in T84 cell monolayers. Our data suggest that the IFN-γ-induced
barrier dysfunction is associated at least in part, with the reduction of
FAK phosphorylation presumably via the downregulation of M1
mAChR signaling. We also tested surgical specimens of colons from
IBD patients in immunohistochemical analysis.2. Materials and methods
2.1. Reagents
Dulbecco's Modiﬁed Eagle's Medium (DMEM) and Ham's F-12,
trypsin-EDTA solution and CCh (Sigma Aldrich, St. Louis, USA), fetal bo-
vine serum (FBS) and Lipofectamine 2000 (Invitrogen, Life Technologies
Corp., CA, USA), atropine sulfate, U0126 and human IFN-γ (Wako Pure
Chemical Industries Ltd., Osaka, Japan), muscarinic toxin 3 (MT-3) and
7 (MT-7) (Peptide Institute, Inc., Osaka, Japan), PF-573228 (PF-228,
Tocris Cookson Ltd., Bristol, UK), [3H]-N-methyl scopolamine chloride
(PerkinElmer, Boston, USA) were obtained from the sources noted. An-
tibodies against MAP kinases (ERK, p38 and JNK), phosphorylated MAP
kinases, MAP2K1, FAK, phosphorylated FAK at tyrosine 397 (Y397), and
β actin were from Cell Signaling Technology, Inc. (Massachusetts, USA)
and those against mAChR M1 (H-120) and mAChR M3 (H-210) were
from Santa Cruz Biotechnology, Inc. (CA, USA).2.2. Cell culture
A human colon cancer cell line, T84, from the Health Protection
Agency Culture Collection (Salisbury, UK) was grown in a humidiﬁed
atmosphere with 5% CO2 at 37 °C in DMEM and Ham's F12 medium
supplemented with 2 mM glutamine, 15 mM HEPES (pH 7.2), 10%
FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were sepa-
rated by trypsinization, and 1 × 106 cells were seeded onto 12-mm
diameter semipermeable ﬁlter supports (Millicell-PCF, 0.4 μm pore
size, Millipore, Ireland) for TERmeasurement and immunoblot analysis.
Cells were cultured for at least 14–21 days prior to use. Human small
intestine epithelial cells (PD015-F, DV Biologics, CA, USA) were grown
in pro-conditioned medium (D-PRO-015, DV Biologics) in collagen
coated culture plates or collagen coated transwell as above.
2.3. Receptor binding assay
After development of 100% conﬂuentmonolayerswith complete dif-
ferentiation, cells were scraped with rubber policeman and washed
with modiﬁed Krebs–Henseleit solution (KHS, comprising NaCl,
120.7 mM; KCl, 5.9 mM; MgCl2, 1.2 mM; CaCl2, 2.0 mM; NaH2PO4,
1.2 mM; NaHCO3, 25.5 mM; and (+)-glucose, 11.5 mM, pH 7.4),
which had been bubbled with a mixture of 95% O2 and 5% CO2. The
whole-cell suspension (1 × 106 cells/ml in KHS) was then incubated
for 2 h with [3H]-N-methyl scopolamine chloride (NMS) and appropri-
ate chemicals in a ﬁnal volume of 1 ml at 4 °C. The assays were per-
formed in duplicate and a nonspeciﬁc binding was deﬁned in the
presence of 1 μM atropine. [3H]-NMS concentrations ranging from 30
to 2500 pM were used in saturation binding experiments, while
600 pMwas used in the competition binding experimentwith the addi-
tion of increasing concentrations of the unlabeled drugs. The reactions
were terminated by centrifuging the incubation solution at 700 ×g for
2 min. The cell pellets were then washed once with 1 ml KHS and
were dissolved in 0.3 M NaOH. The radioactivity was measured by a
liquid scintillation counter (Hitachi Aloka Medical Ltd., Mitaka, Japan).
The mock incubation, in which cells were omitted, gave less than 40
counts per minute per tube and was similar to the background reading.
Protein concentration was measured using a protein assay kit (Bio-Rad
Inc., CA, USA).
2.4. Immunoblotting
Cells were cultured onto 12-mm Millicell-PCF for 14–21 days. The
monolayers on ﬁlters were washed with KHS for three times and
allowed to equilibrate in KHS for 30 min at 37 °Cwith orwithout inhib-
itors. Cells were then stimulated with 100 μM carbachol (CCh) for
5 min. For receptor activation or inhibition by muscarinic ligands, all
drugs were added basolaterally as described previously [26]. Reaction
was terminated by aspirating the medium and rinsed with ice-cold
PBS twice. Cells were then lysed by adding pre-heated 1× SDS sample
buffer (50 mM Tris–HCl, pH 6.8, 10% glycerol, 2% SDS, 1% β-mercapto
ethanol, 0.1% bromophenol blue) to the monolayers and the lysates
were collected into Ependorf tubes and heated for 3 min at 100 °C. Pro-
teins were separated by SDS-PAGE and transferred to polyvinylidene
ﬂuoride membranes. Membranes were probed with appropriate
concentrations of primary antibody. The immunoreactive proteins
were detected by horseradish-peroxidase-labeled secondary antibody
with Amersham ECL advance Western Blotting Detection Kit
(GEHealthcare, Buckinghamshire, UK). The ratio of intensities of signals
was quantiﬁed by densitometry.
2.5. Knockdown of M1 and MAP2K1 by siRNA
Weused predesigned siRNAs (Life Technologies) as follows: CHRM1
(5′–3′)-AGGUCAACACGGAGCUCAAtt and MAP2K1 (5′–3′) GGCCUGAC
AUAUCUGAGGGtt. Transient transfections of siRNA into T84 cells were
637M.R.I. Khan et al. / Biochimica et Biophysica Acta 1842 (2014) 635–645performed using Lipofectamine 2000 as described previously [27].
Brieﬂy, a total of 25 pmol of speciﬁc or scrambled siRNA in
Lipofectamine/Opti-MEM was added to suspension cultures of T84
cells (1 × 106 cells/ml) in antibiotic-free FBS-containing culture
medium. The cells were then seeded onto ﬁlter supports as described
above. Following an overnight incubation, adherent cells were washed
and transferred into antibiotic containing culture medium. After trans-
fection, the cells were cultured for 4 days before experiments.
2.6. Measurement of TER
TER across the cell monolayers wasmeasured using aMillicell ERS-2
epithelial volt–ohmmeter (MerckMillipore, Darmstadt, Germany). The
values (Ω × cm2) were obtained by subtracting the resistance of blank
ﬁlters without cells from the resistance of ﬁlters with cells multiplied
by the effective membrane area of the ﬁlter insert. Inserts having
N1000 Ω × cm2 of TER values were used for the experiments.
2.7. Monolayer injury models
The modulation of barrier function in T84 cell monolayers was
carried out as described previously [4,28]. Brieﬂy, T84 cell monolayers
were treated with ethanol (7%, bilaterally) and incubated at 37 °C for
15 min. After removal of ethanol, monolayers were incubated with
fresh culturemedium and the TERwasmeasured at the times indicated.
In the case of inﬂammation-induced epithelial injury, the monolayers
were treated with IFN-γ (20 ng/ml, basolaterally) as described
previously [23].
2.8. Immunohistochemistry
There were four IBD cases: case 1, a 53-year-old male; case 2, a 31-
year-old male; case 3, a 40-year-old male; and case 4, a 52-year-old
female. All of them were diagnosed as ulcerative colitis but were
refractory to medical therapy and underwent total colectomy. Two
specimens, one from non-inﬂammatory area and another from inﬂam-
matory area, were isolated from each total colectomy sample from IBD
patients. They were ﬁxed with 20% buffered formalin and embedded
in parafﬁn, and cut into tissue sections. After deparafﬁnization, each sec-
tion was incubated with 1:100 dilutions of FAK, P-FAK (Calbiochem,
Darmstadt, Germany), ERK, P-ERK (Cell Signaling Technology) or
mAChR M1 antibody (H-120) (Santa Cruz Biotechnology) for 1 h at
room temperature and then washed three times with PBS. Bound
primary antibody was detected by using anti-rabbit antibody and
diaminobenzidine.
All patients provided written informed consent before surgery. The
research protocol using human materials was approved at the ethical
committee of Asahikawa Medical University.
2.9. Statistical analysis
Binding data were analyzed using PRISM software (Version 5.01,
Graph Pad Software, La Jolla, USA), as described previously [19,29].
Brieﬂy, the data from saturation binding studies were ﬁtted by a one-
site saturation-binding isotherm and the Kd values and the binding
capacity were then calculated. The abundance of themAChRs is indicat-
ed as themaximum binding capacity permg of total cell protein (Bmax).
For the competition studies, the data were analyzed using the Binding–
Competitive Equation of the PRISM software. A two-site model was
adopted only when the residual sums of squares were signiﬁcantly
less (p b 0.05) for a two-site ﬁt to the data than for a one-site by F test
comparison. In immunoblots, the signal intensity was calculated using
the Image J software. Statistical signiﬁcance was evaluated using
Student's t-test and was considered to be signiﬁcant when p values
were less than 0.05. Data are represented as the mean ± SEM with
the number of experiments in parenthesis (n).3. Results
3.1. ERK-dependent FAK phosphorylation regulates the barrier function in
T84 cell monolayers
To investigate the function of ERK and FAK on the barrier function of
T84 cell monolayers, we evaluated TER by using inhibitors for ERK
(U0126) and FAK (PF-228). We ﬁrst examined the effect of inhibitors
on the maintenance of epithelial barrier function. Monolayers were
treated with 10 μM U0126 or 10 μM PF-228 and the change of TER
was measured. As shown in Fig. 1A, U0126 or PF-228 caused a signiﬁ-
cant reduction of TER within 30 min. Immunoblot analysis showed
that U0126 signiﬁcantly inhibited the phosphorylation of both ERK
and FAK but PF-228 inhibited the phosphorylation of FAK alone
(Fig. 1B). We next investigated the effect of U0126 and PF-228 on the
recovery of epithelial barrier function after damage. We employed an
ethanol-induced damage model, in which the treatment with low
noncytotoxic dose of ethanol produced a reversible change of barrier
function [4]. As shown in Fig. 1C, 15-min ethanol treatment caused ap-
proximately 60% reduction of TER. Ethanol-induced reduction of TER
was recovered to about 75–85% 3 h after ethanol removal but the recov-
ery was impaired up to 50–60% in the presence of either U0126 or PF-
228. As shown in Fig. 1D, ethanol treatment signiﬁcantly reduced the
basal phosphorylation levels of both ERK and FAK and these
phosphorylation levels were recovered again after ethanol removal.
The recovery of ERK and FAK phosphorylation was concordant with
the recovery of TER. We also observed that U0126 inhibited the recov-
ery of both ERK and FAK phosphorylation levels but PF-228 inhibited
the recovery of FAK phosphorylation alone. These results suggest that
ERK-dependent FAK phosphorylation regulates the maintenance and
recovery of barrier function in T84 cell monolayers.
3.2. Pharmacological characterization of mAChRs in T84 cells
We have characterized mAChRs in T84 cells by binding methods
using [3H]-NMS as a radioligand. We incubated cells as a whole-cell
suspension for 2 h at 4 °C because we observed stable and saturable
bindings at this time point (T1/2 = 11.8 ± 0.7 min). The total receptor
density was 151.1 ± 13.2 fmol/mg of total cell protein with Kd,
153.1 ± 5.3 pM (Fig. 2A). We examined the pharmacological proﬁles
of the [3H]-NMS binding sites in the cells in competition binding exper-
iments using several subtype selective drugs. MT-7, anM1 selective an-
tagonist, showed a simple high afﬁnity competition (pKi = 9.6 ± 0.3).
However, there was a part insensitive to MT-7 of the [3H]-NMS binding
sites (63.2 ± 3.2% of the total speciﬁc binding), which was not
displaced by MT-7 even at high concentrations (Fig. 2B). Darifenacin,
an M3 selective antagonist, gave a shallow competition curve which
ﬁtted better to a two-site model in computer analyses (Fig. 2C) with
pKi values, 8.8 ± 0.2 and 7.4 ± 0.1 for the high and low afﬁnity compo-
nents, respectively. The proportion of the darifenacin high afﬁnity com-
ponent, which was presumably theM3 subtype, was 65.4 ± 4.6% of the
total speciﬁc binding sites. This proportion showed good agreement
with that of the MT-7 resistant component. Furthermore, in order to
verify the identity of the MT-7-insensitive component as M3 subtype,
displacement by darifenacin was examined in the presence of 0.3 μM
MT-7, which masked more than 95% of the MT-7-sensitive site. As
shown in Fig. 2D, the MT-7-insensitive site was displaced completely
by darifenacin in a monophasic manner with a pKi value of 8.8 ± 0.1,
which is compatible to that of the M3 subtype. AF-DX 116, an M2
selective antagonist showed monophasic competition with low afﬁnity
(pKi 5.9 ± 0.2) (Supplementary Fig. S1A) andMT-3, anM4 selective an-
tagonist did not show any displacement (Supplementary Fig. S1B).
Therefore, we assumed that the M2, M4 or M5 subtype would be none
or very minor population if at all as reported previously [18,30]. Based
on these data, we concluded that T84 cells express mAChRs, M1 and
M3 with the proportion of approximately 35% and 65%, respectively.
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Fig. 1. ERK-dependent FAK phosphorylation maintains and recovers the barrier function of T84 cell monolayers. (A) Effects of U0126 and PF-228 on T84 cell monolayer barrier function.
Treatment of monolayers with 10 μMU0126 or 10 μMPF-228 signiﬁcantly (# p b 0.05) reduced the TER (n = 3). Each data point represents themean of quadruplicate measurements of
TERwith SEM. (B) Effects of U0126 and PF-228 on the levels of ERK and FAK phosphorylation.Monolayerswere incubatedwith fresh culturemedium for 60 minwithout (Control) orwith
10 μMU0126 or 10 μMPF-228. Themonolayers were lysed, separated in SDS-PAGE, blotted and probedwith anti-phospho-ERK (P-ERK) or anti-ERK (ERK) antibodies (n = 3). The same
membranes were stripped and reprobed with anti-phospho-FAK (P-FAK), anti-FAK (FAK), and anti-β actin antibodies as a loading control. U0126 signiﬁcantly (# p b 0.05) inhibited the
phosphorylation of both ERK (white column) and FAK (black column) while PF-228 inhibited the phosphorylation of FAK alone. The ratio of intensities of signal was quantiﬁed by den-
sitometry and was normalized to that without treatment as 100%. (C) Time course of barrier recovery after ethanol injury. T84 cell monolayers were treated with 7% ethanol for 15 min.
After ethanol removal, monolayers were incubated with fresh culture mediumwithout (Control) or with 10 μMU0126 or 10 μM PF-228 (n = 3). (D) Immunoblot analyses of the phos-
phorylation of ERK and FAK in the ethanol injury model (n = 3). Cell lysates were obtained before the addition of ethanol (Normal), 15 min after the addition (EtOH), 60 min after the
removal without (Control) or with 10 μM U0126 (U0126) or 10 μM PF-228 (PF-228). The phosphorylation levels of ERK and FAK were assessed by immunoblot as described in (B).
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M3 subtype in T84 cells.3.3. Stimulation of M1 mAChR leads to phosphorylation of ERK and FAK in
human intestinal epithelial cells
In order to investigate the muscarinic cholinergic response in T84
cells, we stimulated the T84 cell monolayers with 100 μM CCh. The
stimulation of cell monolayers with CCh resulted in an increase in phos-
phorylation of ERK (Fig. 3A) and FAK (Fig. 3B), approximately 60–70%
and 50–60%, respectively above the baseline. The other MAP kinases
p38 and JNK were also phosphorylated by CCh approximately 55–65%
and 80–100%, respectively above the baseline (Supplementary
Fig. S2A, B). These increases in phosphorylation were completely
inhibited by the addition of either 10 μM atropine or 1 μMMT-7 prior
to the stimulation. These results suggest that the phosphorylation of
MAP kinases and FAK is elicited by M1 mAChR. To determine whether
the phosphorylation of FAK by CCh in T84 cells is mediated through
an ERK-dependent pathway, the cell monolayers were stimulated
with CCh under the presence of different concentrations of U0126
or PF-228. U0126 inhibited the phosphorylation of both ERK and
FAK, but PF-228 inhibited the phosphorylation of FAK alone in a dose-
dependent manner (Fig. 3C), suggesting that the M1-elicited FAKphosphorylation is a downstream of ERK phosphorylation. In addition,
in the human intestine epithelial cells, we detected M1 mAChR
(Fig. 2E) that also elicited the similar ERK-dependent FAK phosphoryla-
tion as shown in Fig. 3D.3.4. Ablation of M1 mAChR or MAP2K1 reduces ERK-dependent FAK phos-
phorylation in T84 cells
Genetic ablation ofM1mAChR orMAP2K1 (an upstreamactivator of
ERK) in T84 cells with speciﬁc siRNA reduced their protein expression
levels compared to those in the cells treated with nonspeciﬁc control
siRNA. As a result of these knockdown of M1 (65.5 ± 3.6% signiﬁcant
reduction) or MAP2K1 (61.8 ± 1.6% signiﬁcant reduction) caused a
signiﬁcant reduction of CCh-induced ERK and FAK phosphorylation in
T84 cells. There were 4.5 ± 0.4 and 1.8 ± 0.2 fold increase in the
CCh-induced phosphorylation of ERK and FAK, respectively in the
monolayers transfected with control siRNA. In contrast, knockdown of
M1 caused 2.0 ± 0.3 and 1.2 ± 0.1 fold increase (Fig. 4A), and that of
MAP2K1 caused 1.6 ± 0.4 and 1.2 ± 0.2 fold increase (Fig. 4B) in the
phosphorylation of ERK and FAK, respectively. These ﬁndings are
consistent with those in pharmacological analyses, supporting the
conclusion that FAK is phosphorylated via M1 mAChR-mediated ERK
activation.
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after ethanol-induced epithelial injury
We assumed that the stimulation of M1mAChRmight have positive
effects on the restitution of epithelial barrier function after ethanol inju-
ry because M1 also elicited ERK-dependent FAK phosphorylation as
shown in Figs. 3 and 4. To verify this hypothesis, cell monolayers bathed
in fresh culture medium were stimulated by CCh after ethanol-induced
epithelial injury. As shown in Fig. 5, addition of CCh signiﬁcantly aug-
mented the recovery of TER as compared to control. The CCh-induced
increase in TER was canceled in the presence of either atropine, or
MT-7 (Fig. 5A). The CCh-induced increase in TER was also canceled in
the presence of either U0126 (Fig. 5B) or PF-228 (Fig. 5C) in a dose-
dependent manner, suggesting that the stimulation of M1 mAChR
facilitates the restitution of barrier function through ERK-dependent
FAK phosphorylation pathway after ethanol injury. However, there
was no signiﬁcant change of TER after addition of either CCh or
mAChR inhibitors in the conﬂuent monolayers without injury (data
not shown), presumably because of the maximum barrier function
that is already established.
3.6. Attenuation of TER and mAChR signaling after IFN-γ treatment
Treatment of monolayers with IFN-γ (20 ng/ml) decreased the TER
in a time-dependentmanner as shown in Fig. 6A. Since IFN-γ treatment
compromised the epithelial barrier function, we have investigated the
signaling aspect of mAChRs in the IFN-γ treatment. The monolayers
were treated with IFN-γ for 48 h and were then stimulated with CCh,
and the phosphorylation levels of ERK (Fig. 6B) and FAK (Fig. 6C)were compared with those of cells without IFN-γ treatment. There
was approximately 50 ± 3.7% and 35 ± 2.7% signiﬁcant reduction of
CCh-induced increase in the phosphorylation levels of ERK and FAK,
respectively after IFN-γ treatment. As shown in Fig. 6B, there was slight
increases (but not signiﬁcant) in the basal levels of ERK and ERK phos-
phorylation after IFN-γ treatment. In contrast, IFN-γ treatment signiﬁ-
cantly decreased the basal level of FAK phosphorylation 44.2 ± 3.9%
as compared to the control monolayers without any change of total
FAK levels (Fig. 6C). These results suggest that downregulation of FAK
phosphorylation participates in the IFN-γ-induced reduction of TER.
We further investigated whether IFN-γ alters the expression levels
of mAChRs that elicit the phosphorylation of ERK and FAK. As shown
in Fig. 6D, there was 51.3 ± 2.3% and 14.4 ± 5.0% reduction of the sig-
nal intensity for theM1 and M3, respectively. The reduction of receptor
subtypes was also conﬁrmed in binding studies as shown in Fig. 6E. The
densities of mAChRs in the control T84 cells were 160.8 ± 3.8,
63.6 ± 1.8 and 97.2 ± 2.3 fmol/mg of total cell protein for total, M1
and M3 subtypes, respectively, whereas in the IFN-γ treated cells the
densities were 82.1 ± 3.8, 23.0 ± 2.5 and 59.1 ± 1.3 fmol/mg of total
cell protein for total, M1 and M3 subtypes, respectively. There was
63.9 ± 1.8% and 39.2 ± 2.3% reduction of the density of [3H]-NMS
binding sites, for the M1 and M3 subtypes, respectively in the cells
from IFN-γ treated monolayers compared to those from the control
monolayers (Fig. 6F). Thus the IFN-γ treatment caused a reduction of
mAChR density and the reduction was signiﬁcantly higher in M1 sub-
type as compared to that of M3. These data suggest that the reduction
of M1 mAChR under inﬂammatory condition might be relevant to the
attenuation of ERK/FAK phosphorylation and to barrier dysfunction as
well.
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(C) ERK-dependent FAK phosphorylation. The monolayers were stimulated by none (−), by 100 μMCCh (+), plus U0126, or PF-228 at various concentrations (1–30 μM) as indicated in
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and that of FAK alone was suppressed by PF-228 (n = 3). The ratio of intensities of signal was quantiﬁed by densitometry and was normalized to that without stimulation as 100%.
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phosphorylation in the colonic epithelium from IBD patients
We compared the expression levels of M1mAChR, ERK and FAK and
the phosphorylation levels of the kinases in between a relatively non-
inﬂammatory area and an inﬂammatory area of each colon resected
from IBD patients by using immunohistochemistry method as shown
in Fig. 7. Although one out of four cases had severe inﬂammation
(case 3) so that the colonic epitheliumwas denuded almost completely,
there was a discernible reduction of M1 mAChR density in the
inﬂammatory area of the epithelium as compared to the relatively
non-inﬂammatory area (Fig. 7). These results are concordant with
the in vitro experiment of IFN-γ-induced inﬂammation in T84 cellmonolayers. In contrast, the expression levels of the kinases were
increased slightly and the phosphorylation levels of the kinases were
also increased considerably in the epithelial cells in inﬂammatory
areas as compared to in non-inﬂammatory areas (Fig. 7). These
increases, especially that of FAK phosphorylation disagreed with the
IFN-γ-induced decrease in a cell culture system (Fig. 6C). However,
there must be not only a pro-inﬂammatory system but also an anti-
inﬂammatory system as well functioning at the same time in vivo. We
speculated that these increases were a part of compensatory cellular
mechanisms which reinforce the barrier function in the inﬂammatory
condition. However, we have to be very careful to interpret these results
in clinical samples, not only because a diverse range of inﬂammatory
mediators and cytokines participated in the pathology of IBD, but also
Control  M1 
+ + 
A M1 siRNA 
P-ERK 
Fo
ld
 in
cr
ea
se
 
siRNA Control M1 
P-FAK 
Fo
ld
 in
cr
ea
se
 
Control M1 
M1 
P-ERK 
ERK 
FAK 
Actin 
P-FAK 
CCh 
siRNA 
P-ERK 
ERK 
B MAP2K1 siRNA 
Fo
ld
 in
cr
ea
se
 
Control MAP2K1 
P-FAK 
Fo
ld
 in
cr
ea
se
 
Control MAP2K1 
P-ERK 
siRNA 
FAK 
P-FAK 
MAP2K1 
Actin 
Control  MAP2K1 
+ + CCh 
siRNA 
Fig. 4.KnockdownofM1mAChRorMAP2K1 suppresses the phosphorylation of ERK and FAK in T84 cells. (A) Knockdownby siRNA targetingM1mAChR signiﬁcantly (#p b 0.05) reduced
the CCh-induced phosphorylation of ERK and FAK in T84 cells (n = 3). (B) Knockdownby siRNA targetingMAP2K1 signiﬁcantly (# p b 0.05) reduced the CCh-induced phosphorylation of
ERK and FAK in T84 cells (n = 3).
A 
TE
R
 r
ec
ov
er
y 
(%
) 
Time (min) 
B CCh 
CCh + U0126 1 µM 
CCh + U0126 3 µM 
CCh + U0126 10 µM 
CCh + U0126 30 µM 
Control * 
* 
* * * 
Time (min) 
TE
R
 r
ec
ov
er
y 
(%
) 
CCh 
CCh + PF-228 1 µM 
CCh + PF-228 3 µM 
CCh + PF-228 10 µM 
CCh + PF-228 30 µM 
Control 
* 
* * * 
* 
C 
Time (min) 
TE
R
 r
ec
ov
er
y 
(%
) 
Fig. 5. Stimulation of M1mAChR enhances the TER recovery after ethanol-induced barrier injury. (A) T84 cell monolayers were treatedwith ethanol for 15 min, and then incubatedwith
fresh culture mediumwithout (Control), or with 100 μM CCh (CCh), plus 10 μM atropine (CCh + ATR), or 1 μMMT-7 (CCh + MT-7). There was a signiﬁcant increase in the recovery of
barrier function by CCh (* p b 0.05), whichwas canceled by either ATR orMT-7 (n = 5). (B) U0126 or (C) PF-228 (1–30 μM) canceled the CCh-induced increase in the recovery of barrier
function in a dose-dependent manner (n = 3). Each data point represents the mean of quadruplicate measurements of TER with SEM.
641M.R.I. Khan et al. / Biochimica et Biophysica Acta 1842 (2014) 635–645
R
ed
uc
tio
n 
de
ns
ity
 (%
) 
M1 M3 
F 
Total M1 M3 
Bi
nd
in
g 
 
fm
ol
/m
g 
ce
ll 
pr
ot
ei
n 
E 
R
el
at
iv
e 
in
te
ns
ity
 (%
) 
CCh + + 
Control IFN-
* 
P-ERK  
ERK 
CCh + + 
Control IFN-
Actin 
B 
D M1 
Actin 
M3 
Control IFN-
M1 M3 R
el
at
iv
e 
in
te
ns
ity
 (%
) 
A 
Time (h) 
TE
R
 (
cm
2 ) 
C 
P-FAK 
FAK 
+ + CCh 
Control IFN-
Actin 
Control IFN-
R
el
at
iv
e 
in
te
ns
ity
 (%
) 
CCh + + 
* 
&
Fig. 6.Attenuation of TER andmAChR signaling after IFN-γ treatment. (A) Treatment ofmonolayerswith IFN-γ (20 ng/ml) decreased the TER in a time-dependentmanner. The signiﬁcant
reduction of TER (# p b 0.05)was observed from 24 h after treatment (n = 5). (B) Attenuated phosphorylation of ERK.Monolayerswere treatedwith IFN-γ for 48 h and then stimulated
by none (−) or 100 μMCCh (+). The phosphorylation levels and the ratio of intensities of ERKwere assessed by immunoblot as described in Fig. 1. (C) Attenuated phosphorylation of FAK.
The samemembranes of ERK phosphorylation experimentswere reprobedwith anti-phospho-FAK (P-FAK) and anti-FAK (FAK) antibodies. The basal FAK phosphorylationwas decreased
after IFN-γ treatment as compared to control (& p b 0.05). CCh-induced phosphorylation of both ERK and FAKwas signiﬁcantly (# p b 0.05) attenuated in the IFN-γ treatedmonolayers as
compared to control (n = 3). (D) Representative immunoblots of M1 andM3 levels after IFN-γ treatment. A 48-h IFN-γ treatment signiﬁcantly (# p b 0.05) reduced the levels of M1 but
not much ofM3 as compared to control (n = 3). (E) Reduction of the total, M1 andM3mAChRs density after IFN-γ treatment. A 48-h IFN-γ treatment signiﬁcantly (# p b 0.05) reduced
the density of total, M1 andM3mAChRs as compared to control (n = 3). (F) The reduction ofM1was signiﬁcantly higher than that ofM3. The percentageswere calculated taking the Bmax
value of control as 100%.
642 M.R.I. Khan et al. / Biochimica et Biophysica Acta 1842 (2014) 635–645because multiple factors such as a phase of disease, chemotherapy
regimens, etc. may be involved in the modulation of ERK/FAK signaling
in the IBD patient in vivo.
4. Discussion
In this study, we have shown that treatment of T84 cell monolayers
with U0126 or PF-228 signiﬁcantly reduced the TERwith the concurrent
reduction of ERK/FAK phosphorylation levels. Our data exhibited that
U0126 inhibited the phosphorylation of both ERK and FAK but PF-228
inhibited the phosphorylation of FAK alone not only in the steady
phase but also in the recovery phase (Fig. 1). These ﬁndings indicate
that both ERK and FAK activities are required in the maintenance and
recovery of the barrier function in T84 cell monolayers and suggest
that the activation of FAK is dependent on ERK activity.
We, next, exhibited that human intestinal epithelial cells including
primary culture and T84 cells express M1 and M3 mAChRs (Fig. 2),
based on pharmacological proﬁling and on immunoblot analyses. We
have demonstrated that stimulation of T84 cells by CCh increased the
phosphorylation of MAP kinases (ERK, p38 and JNK) and FAK. The
CCh-induced increase in phosphorylation of both MAP kinases andFAK was completely inhibited in the presence of either subtype-
nonselective mAChR antagonist (atropine) or M1 selective mAChR
antagonist (MT-7). These results suggest that the phosphorylation of
MAP kinases and FAK in human intestinal epithelial cells was mediated
by M1 mAChR.
Wehave, then, focused on ERKand FAK in relation to themodulation
of barrier function. We have found that the CCh-induced phosphoryla-
tion of FAK in human intestinal epithelial cells is a downstream of ERK
phosphorylation, becauseU0126 inhibited theCCh-induced phosphory-
lation of both ERK and FAK but PF-228 inhibited the phosphorylation of
FAK alone (Fig. 3). In addition, genetic ablation of M1 mAChR or
MAP2K1 by speciﬁc siRNA in T84 cells signiﬁcantly suppressed the
CCh-induced phosphorylation of both ERK and FAK (Fig. 4A and B),
supporting the conclusion drawn from pharmacological analyses. Liu
et al. [31] demonstrated that ERK-mediated HGF-induced phosphoryla-
tion of paxillin resulted in the recruitment and activation of FAK
in mIMCD-3 epithelial cells. Similar results of ERK-dependent FAK
activation have also been reported in various other tissues or cell
models [32,33]. However, there are also some contradictory reports.
Flinder et al. [34] showed that EGF induced FAK-dependent ERK activa-
tion in hepatocytes through Rac1-NADPH oxidase pathway. These
ERK
FAK
P-FAK
M1
P-ERK
Case 1 Case 2 Case 3 Case 4 
N I N I N I N I 
Fig. 7. Immunohistochemical analyses of colonic epithelium from IBD patients. Two specimens, one from non-inﬂammatory area (N) and another from inﬂammatory area (I), were
analyzed in each total colectomy sample from four IBD patients. They were stained with anti-M1, ERK, P-ERK, FAK or P-FAK antibodies as described in the “Methods” section (scale bar
in the top left panel shows 100 μm).
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different cell types used in the respective studies.
ERK is believed to be involved in the regulation of barrier function
andparacellular permeability. Several researchers reported an enhance-
ment of the epithelial barrier functions in T84 cell monolayers via MAP
kinase signaling pathway by up-regulating the tight junction proteins
[12,13]. On the other hand, several studies implicate a signiﬁcant role
of FAK signaling pathway in the barrier function and paracellular
permeability. Recent studies have demonstrated that FAK activity is
necessary for the barrier enhancement [6,7] and that FAK is an integrat-
ed component of the occludin/ZO-1 complex [5,35]. In this study, we
also showed that FAK participated in the augmentation of the barrier
recovery by CCh in T84 cell monolayers (Fig. 5). These data including
ours suggest that the enhancement of TER recovery is mediated by M1
mAChR, via the activation of ERK-dependent FAK signaling pathways.
A leaky intestinal barrier is considered an important contributor to
the pathology of IBD, which includes Crohn's disease and ulcerative
colitis [36,37]. Indeed, a decline in barrier function of the intestinal
epithelium has been shown to correlate positively with the degree
of mucosal inﬂammation in IBD patients [38]. Participation of pro-
inﬂammatory cytokines in the pathophysiology of IBD is well
recognized and IFN-γ, one of those cytokines, has been implicated in
epithelial barrier dysfunction [39]. In our study, we have shown that
IFN-γ treatment decreased the TER of T84 cell monolayers (Fig. 6A).
We identiﬁed that IFN-γ treatment decreased the basal phosphoryla-
tion levels of FAK at the same time (Fig. 6C). These results are consistent
with theﬁndings by Leeb et al. [40], which showed that IFN-γ treatment
decreased the phosphorylation levels of FAK in colonic lamina propria
ﬁbroblast (CLPF). They also demonstrated the reduction of FAK
phosphorylation levels in CLPF obtained from the active Crohn's disease
patients. On the other hand, we found that the phosphorylation level of
ERK was increased slightly in IFN-γ treatment (Fig. 6B). We speculate
that under inﬂammatory conditions, FAK phosphorylation is downreg-
ulated via ERK-independent pathway and the reduction of FAKphosphorylation may be relevant to the mechanism of IFN-γ-induced
barrier dysfunction in T84 cell monolayers. Further studies are neces-
sary to uncover the complex mechanism of these signal transductions.
The ERK/FAK signaling viamAChRswas also signiﬁcantly attenuated
in IFN-γ treatment (Fig. 6B and C). Cholinergic hyporesponsiveness is a
well-known phenomenon in colitis. Dextran sulfate sodium (DSS)-
induced colitis in mice results in a profound hyporesponsiveness of
the colonic epithelium to prosecretory agents and a complete loss of
response to mAChR activation [41]. Immunological results revealed
that the IFN-γ treatment caused a signiﬁcant reduction of M1 mAChR
but notmuchofM3 (Fig. 6D). In addition, binding experiments also sup-
ported the reduction of the density of M1 subtype signiﬁcantly higher
than that of M3 in the T84 cells after treatment with IFN-γ (Fig. 6E
and F). We have speculated that the reduction of M1 mAChR density
on the cell surface of colonic epitheliummay be one of themechanisms
in the cholinergic hyporesponsiveness in inﬂammatory conditions.
Finally, immunohistochemical staining of colonic epithelium from
IBD patients has revealed that there was apparent reduction of M1
mAChR density in inﬂammatory area as compared to the relatively
non-inﬂammatory area of the colonic epithelium (Fig. 7). Recently, we
reported that colitis induction inmousemodel resulted in the reduction
of epithelial mAChRs where M1 subtype was highly susceptible to in-
ﬂammation than M3 [19]. Although the mechanism of this reduction
is not clariﬁed yet, our data provide direct evidence that the reduction
of mAChRs could be a fundamental mechanism of inﬂammatory cholin-
ergic hyporesponsiveness. Our data also revealed that the expression
levels of ERK and FAK were slightly increased in the inﬂammatory
areas and the phosphorylation levels of the kinases were also increased
considerably (Fig. 7). These results are concordant with the previous
studies, in which, using cell cultures or isolated crypts in biopsies
from IBD patients, ERK was not only over-expressed but also highly
phosphorylated during the active phase of IBD [42,43]. In the case of
FAK, this is the ﬁrst report showing the upregulation in the colonic
epithelium of IBD patients. In a mouse model also, we reported the
644 M.R.I. Khan et al. / Biochimica et Biophysica Acta 1842 (2014) 635–645increase in the expression level of FAK [20]. Our results in this
manuscript suggest that FAK functions in themaintenance and recovery
of the barrier function in colonic epithelium. This is concordant with re-
cent ﬁndings by Owen et al. which have shown that the FAK knockout
mice exhibited earlier onset and increased severity of DSS-induced
colitis as compared to control animals. The colonic epithelial repair
was also impaired signiﬁcantly in the absence of FAK [44]. Since the
patients with IBD represent a heterogeneous spectrum of pathological
featureswith the participation of a diverse range of inﬂammatorymedi-
ators, it is difﬁcult to conclude how FAK is involved in the pathology.
However, we could speculate that the activity of FAK might be relevant
with the episode of inﬂammation. In some phase of inﬂammation, FAK
expression and activity may be upregulated to compensate the epitheli-
al damage. Further studies are required in the future to elucidate the
involvement of FAK in the pathology of IBD.
In conclusion, our data show that human intestinal epithelial cells
express M1 mAChR that positively regulates the barrier function
through ERK-dependent FAK phosphorylation pathways. In a patho-
physiological aspect, reduction of FAK phosphorylation in T84 cells
may be relevant to the IFN-γ-induced barrier dysfunction. The attenuat-
ed phosphorylation of ERK and FAK upon muscarinic stimulation
after IFN-γ treatment is presumably due to the reduction of M1
mAChR density on the cells. Although further studies are necessary,
these ﬁndings could implicate an important role of M1 mAChR for the
maintenance and restitution of intestinal epithelial barrier function in
pathophysiological conditions.
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